Sunday 18 October 2026
Export INO’s income statement to Excel — free account
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024. In the quarter to June 2026, revenue fell 83.2%, EPS grew 88.5% and free cash flow grew 13.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.99
0.05
−4.81%
Follow INO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.92 | 0.99 | 1.34 | 0.74 | |
Current Ratio |
1.00 | 1.04 | 1.40 | 0.79 | |
Net Debt/EBITDA |
2.05 | 1.78 | 3.49 | 2.49 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.00 | 1.10 | (5.14) | 0.47 | |
Capex/Depreciation |
0.00 | 0.00 | (0.18) | (0.08) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.22) | (0.31) | (0.41) | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.31) | (0.42) | (0.41) | |
Cash per Share |
0.45 | 0.55 | 1.25 | 0.97 | |
Shareholders Equity per Share |
0.05 | 0.09 | 0.51 | (0.15) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.05 | 0.09 | 0.51 | (0.15) | |
Free Cash Flow |
(18.05) | (21.59) | (19.50) | (21.64) | |
Working Capital |
0.00 | 1.52 | 17.45 | (14.64) | |
Capital Expenditures |
— | — | (0.13) | (0.07) | |
Net Current Asset Value |
(5.11) | (4.27) | 10.91 | (21.93) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 1.42 | |
Average Payables |
13.89 | 11.33 | 14.34 | 16.14 | |
Average Assets |
58.82 | 68.52 | 93.75 | 88.22 | |
Average Common Equity |
16.45 | 28.66 | 46.30 | 32.91 |
Columns are period end dates